Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:12:12 EDT Sun 05 May 2024
Enter Symbol
or Name
USA
CA



News for U:CYTK from 2023-05-04 to 2024-05-03 - 51 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-02 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-29 16:00U:CYTKNews ReleaseCytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
2024-04-24 16:00U:CYTKNews ReleaseCytokinetics to Announce First Quarter Results on May 8, 2024
2024-04-10 07:30U:CYTKNews ReleaseCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
2024-04-05 07:30U:CYTKNews ReleaseCytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
2024-04-05 07:30U:CYTKNews ReleaseCytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
2024-04-02 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-04-01 16:00U:CYTKNews ReleaseCytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
2024-03-25 08:15U:CYTKNews ReleaseCytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
2024-03-04 16:00U:CYTKNews ReleaseCytokinetics to Participate in March Investor Conferences
2024-03-01 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-29 07:30U:CYTKNews ReleaseCytokinetics Joins Global Initiative to Recognize International Rare Disease Day
2024-02-28 07:30U:CYTKNews ReleaseCytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
2024-02-27 16:00U:CYTKNews ReleaseCytokinetics Reports Fourth Quarter 2023 Financial Results
2024-02-13 16:00U:CYTKNews ReleaseCytokinetics to Announce Fourth Quarter Results on February 27, 2024
2024-02-06 16:00U:CYTKNews ReleaseCytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-01-29 07:30U:CYTKNews ReleaseCytokinetics Announces Recipients of Its Sixth Annual Communications Grant Program
2024-01-25 07:30U:CYTKNews ReleaseCytokinetics Presents New Data at CMR 2024 From FOREST-HCM, the Open Label Extension Clinical Trial of Aficamten
2024-01-18 13:00U:CYTKNews ReleaseCytokinetics Announces New Data From FOREST-HCM to be Presented at CMR 2024
2024-01-03 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-02 16:00U:CYTKNews ReleaseCytokinetics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-27 07:30U:CYTKNews ReleaseCytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
2023-12-26 16:00U:CYTKNews ReleaseCytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
2023-12-07 07:30U:CYTKNews ReleaseCytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
2023-12-01 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-29 16:00U:CYTKNews ReleaseCytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND
2023-11-03 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-11-02 16:00U:CYTKNews ReleaseCytokinetics Reports Third Quarter 2023 Financial Results
2023-11-01 16:00U:CYTKNews ReleaseCytokinetics to Participate in Upcoming Investor Conferences
2023-10-23 16:00U:CYTKNews ReleaseCytokinetics to Announce Third Quarter Results on November 2, 2023
2023-10-19 07:30U:CYTKNews ReleaseCytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
2023-10-06 12:45U:CYTKNews ReleaseCytokinetics Presents Baseline Characteristics From SEQUOIA-HCM at the HCM Society Scientific Sessions
2023-10-05 16:00U:CYTKNews ReleaseCytokinetics to Host Virtual Investor & Analyst Day on October 19, 2023
2023-10-03 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-10-02 16:00U:CYTKNews ReleaseCytokinetics Announces Upcoming Presentations at the 2023 HCMS Scientific Sessions and the HFSA Annual Scientific Meeting
2023-09-28 07:30U:CYTKNews ReleaseCytokinetics Announces Call for Proposals for Its Sixth Annual Communications Grant Program
2023-09-07 16:00U:CYTKNews ReleaseCytokinetics to Participate in Upcoming Investor Conferences
2023-09-06 07:30U:CYTKNews ReleaseCytokinetics Announces Start of ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
2023-09-01 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-03 16:00U:CYTKNews ReleaseCytokinetics Reports Second Quarter 2023 Financial Results
2023-08-01 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
2023-07-27 16:00U:CYTKNews ReleaseCytokinetics to Announce Second Quarter Results on August 3, 2023
2023-07-05 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-20 07:30U:CYTKNews ReleaseCytokinetics Announces Start of MAPLE-HCM, a Phase 3 Clinical Trial of Aficamten Compared to Metoprolol in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
2023-06-02 16:00U:CYTKNews ReleaseCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2023-06-01 16:00U:CYTKNews ReleaseCytokinetics to Participate in Upcoming Investor Conferences
2023-05-20 10:31U:CYTKNews ReleaseCytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress
2023-05-15 16:00U:CYTKNews ReleaseCytokinetics Announces Three Upcoming Presentations at the European Society of Cardiology Heart Failure 2023 Congress
2023-05-11 07:30U:CYTKNews ReleaseCytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4021586
2023-05-08 16:00U:CYTKNews ReleaseCytokinetics to Participate in the JMP Securities Life Sciences Conference
2023-05-04 16:00U:CYTKNews ReleaseCytokinetics Reports First Quarter 2023 Financial Results